Salarius Pharmaceuticals (now Decoy Therapeutics) Faces Nasdaq Delisting, Proposes Reverse Stock Split and Highly Dilutive Equity Plan

summarizeSummary

Salarius Pharmaceuticals, recently renamed Decoy Therapeutics Inc., is seeking shareholder approval for a reverse stock split to avoid Nasdaq delisting and a new, highly dilutive equity incentive plan, following a recent merger and ongoing listing compliance issues.

check_boxKey Events

• Nasdaq Delisting Threat

  The company received a delisting notice from Nasdaq for failing to meet the $1.00 minimum bid price requirement and has appealed the decision, staying the delisting process.

• Proposed Reverse Stock Split

  Shareholders will vote on a reverse stock split at a ratio between 1-for-4 and 1-for-15, aimed at increasing the stock price to meet Nasdaq's initial listing criteria of $4.00 per share and the ongoing $1.00 minimum bid price requirement.

• Highly Dilutive Equity Incentive Plan

  A new 2026 Equity Incentive Plan is proposed, initially reserving 1,100,000 shares, which represents a significant portion of current outstanding shares, and includes an evergreen provision for annual increases of 6% (2027) and 5% (2028-2036) of outstanding common stock.

• Recent Merger and Name Change

  The company completed a merger with Decoy Therapeutics Inc. in November 2025 and officially changed its name to Decoy Therapeutics Inc. on January 8, 2026, with its shares now trading under the symbol 'DCOY'.

auto_awesomeAnalysis

Salarius Pharmaceuticals, now operating as Decoy Therapeutics Inc., is at a critical juncture, facing potential delisting from Nasdaq due to its failure to meet the minimum bid price requirement. The company has appealed the delisting notice, and the proposed reverse stock split is a crucial step to regain compliance and meet initial listing standards following its recent merger. While necessary for continued public listing, a reverse split often signals underlying financial distress. Concurrently, the proposed new equity incentive plan, which includes an initial allocation of 1.1 million shares and significant evergreen provisions, represents substantial potential dilution for existing shareholders. These actions collectively highlight the company's urgent need to stabilize its market presence and secure future capital, but also reflect the challenges inherent in its current valuation and operational status.